Pregnancy hormones may speed up cannabis processing, study finds

NCT ID NCT04374773

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how two hormones that rise during pregnancy—estradiol and cortisol—affect the way the body breaks down THC, the main active ingredient in cannabis. Fourteen healthy women of childbearing age took part. Researchers measured THC levels in the blood after taking a synthetic THC pill (dronabinol). The goal was to better understand how cannabis use might affect pregnant women and their developing babies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

14 people

The number who actually took part.

Started

Oct 2020

Finished

Feb 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 45 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy, premenopausal women ages 21-45 years old * Body mass index (BMI) \<30 kg/m2 * Regular menstrual periods (monthly, cycle 28-35 days in length) * Willingness to use nonhormonal methods of contraception during the study period Exclusion Criteria: * History of diabetes or significant cardiac, kidney (eGFR\<60 mL/min/1.73m2), gastrointestinal or liver disease * History of blood clots or stroke * Allergy to dronabinol, synthetic steroids, or any other chemically related drug or steroid * Current or recent ingestion (\<3 weeks) of any medication or herbal supplement known to be an inducer or inhibitor of CYP2C9, CYP3A4 or UGT. These include some anticoagulants, anti-psychotics, antibiotics, antifungal agents, antidepressants, anti-retroviral agents and herbal supplements (or other over-the-counter medications and supplements). Subjects who are taking any of these prescription drugs will not be asked to discontinue treatment but will be ineligible for study participation. Subjects taking excluded over-the-counter medications and/or supplements will be given the option of discontinuing these for 1 month prior to study participation. * Current pregnancy or lactation * History of use of illicit drugs or smoking within the last year * Any recreational or medicinal use of cannabis or other forms of THC within 3 months * Current use of amphetamines, anticholinergic drugs or antidepressants * History of seizure disorder or psychiatric illness (mania or schizophrenia; major depression within the past year or \>2 episodes lifetime) * Current use of live or live attenuated vaccines * Personal or family (1st degree relative) history of breast or ovarian cancer * Systemic disease (cancer, auto-immune disease, chronic infection, etc) * Current or recent (within 6 months) use of hormonal contraceptives * History of severe hypertriglyceridemia (\>300 mg/dL or history of acute pancreatitis) * Uncontrolled hypertension (BP\>140/90) * Allergy to sesame oil * Anemia (Hct \<34 g/dL) * Extensive skin disease (eczema, psoriasis, etc) that would preclude use of transdermal estradiol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cannabis use are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Nina Isoherranen

    Seattle, Washington, 98125, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.